Neurology · AnticonvulsantRegulatory Approvalregulatorynear-term

FDA Grants AP Status for Gabapentin ANDA213603 by Zhejiang Yongtai

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:33:49 PM

Assessment confidence: 74% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Zhejiang Yongtai's Gabapentin ANDA213603 signifies a shift in the competitive landscape of the generic anticonvulsant market. This development necessitates close monitoring of pricing strategies and market share implications for existing players in the Gabapentin segment. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on pricing and market share dynamics in the Gabapentin segment. The strongest clinical anchor is The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 8 regulatory and 1 competitive items passed relevance filtering for Gabapentin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This approval status may enhance Zhejiang Yongtai's position in the generic market for Gabapentin, increasing competition against existing manufacturers.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (gabapentin); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but ongoing monitoring of market entry and competitive responses will be crucial for regulatory positioning.

Key Risks

Elevated medium regulatory exposure for Gabapentin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased competition from Zhejiang Yongtai could pressure pricing and market share for current Gabapentin manufacturers, potentially impacting revenue streams.
Portfolio teams should assess the impact of this approval on pricing and market share dynamics in the Gabapentin segment.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market entry of Zhejiang Yongtai's Gabapentin product.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source

The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Shaping Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Single-Dose vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gabapentin
existing manufacturers

Commercial impact

medium

Increased competition from Zhejiang Yongtai could pressure pricing and market share for current Gabapentin manufacturers, potentially impacting revenue streams.

Regulatory impact

medium

The approval status indicates compliance with FDA standards, but ongoing monitoring of market entry and competitive responses will be crucial for regulatory positioning.

What to watch

Monitor the launch timeline and market entry of Zhejiang Yongtai's Gabapentin product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.